In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson, the plaintiffs successfully overcame a motion to dismiss. At the heart of the case is J&J’s legal strategy against biosimilar competitors, including...more
11/18/2024
/ Antitrust Provisions ,
Biosimilars ,
Health Care Providers ,
Insurance Industry ,
Inter Partes Review (IPR) Proceeding ,
Johnson & Johnson ,
Life Sciences ,
Misrepresentation ,
Motion to Dismiss ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Settlement ,
USPTO